<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296800</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-454</org_study_id>
    <nct_id>NCT03296800</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Non-Randomized, Fixed-Sequence Composite Study to Evaluate the Effects of Probenecid, Rifampin, and Verapamil on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug-drug interaction when given the study drug,&#xD;
      bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin.&#xD;
      The study is to evaluate how safe the study drug is and how well the study drug is tolerated&#xD;
      when taken with probenecid, verapamil or rifampin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, a total of 48 healthy subjects were enrolled and assigned to one of three&#xD;
      groups of 16 subjects. Each group participated in an open-label, non-randomized,&#xD;
      fixed-sequence studies to assess potential interaction of bexagliflozin tablets, 20 mg with&#xD;
      probenecid, rifampin or verapamil.&#xD;
&#xD;
      Sequence 1: Bexagliflozin/probenecid Sixteen healthy subjects were dosed with bexagliflozin,&#xD;
      qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects&#xD;
      took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one&#xD;
      bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg,&#xD;
      bid.&#xD;
&#xD;
      Sequence 2: Bexagliflozin/rifampin Sixteen healthy subjects were dosed with bexagliflozin, qd&#xD;
      and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one&#xD;
      bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects&#xD;
      took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.&#xD;
&#xD;
      Sequence 3: Bexagliflozin/verapamil Sixteen healthy subjects were dosed with bexagliflozin,&#xD;
      and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one&#xD;
      bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a&#xD;
      bexagliflozin tablet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Actual">December 6, 2017</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent Terminal Elimination Half-life)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 0-48 hr</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bexagliflozin/probenecid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexagliflozin/rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexagliflozin/verapamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin 20 mg, tablet; qd</description>
    <arm_group_label>Bexagliflozin/probenecid</arm_group_label>
    <arm_group_label>Bexagliflozin/rifampin</arm_group_label>
    <arm_group_label>Bexagliflozin/verapamil</arm_group_label>
    <other_name>EGT0001442, EGT0001474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
    <description>Probenecid tablets, 500 mg; bid</description>
    <arm_group_label>Bexagliflozin/probenecid</arm_group_label>
    <other_name>Probalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin, 600 mg (2 x 300 mg capsules); qd</description>
    <arm_group_label>Bexagliflozin/rifampin</arm_group_label>
    <other_name>Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Verapamil hydrochloride tablet, 120 mg; qd</description>
    <arm_group_label>Bexagliflozin/verapamil</arm_group_label>
    <other_name>Verelan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects meeting the following Criteria were included::&#xD;
&#xD;
          1. Between 18 and 55 years of age at screening, inclusive, and in good health based on&#xD;
             medical history, physical examination, electrocardiogram and routine laboratory tests.&#xD;
&#xD;
          2. Had a body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2 at screening, inclusive.&#xD;
&#xD;
          3. Abstained from tobacco consumption for at least 3 months prior to screening.&#xD;
&#xD;
          4. Had adequate venous access at multiple sites in both arms.&#xD;
&#xD;
          5. Willing and able to be confined to the clinical research facility as required by the&#xD;
             protocol.&#xD;
&#xD;
          6. Able to comprehend the explanation of the informed consent and willing to provide&#xD;
             written informed consent in accordance with institutional and regulatory guidelines.&#xD;
&#xD;
        Subjects who met any of the following criteria were excluded from the study:&#xD;
&#xD;
          1. A clinically significant history of allergy to drugs or latex (at the Investigator's&#xD;
             discretion.)&#xD;
&#xD;
          2. A history of alcohol or drug dependence in the last 12 months.&#xD;
&#xD;
          3. A history of donation of 400 mL of whole blood within two months, 200 mL of whole&#xD;
             blood within one month, or blood components within 14 days prior to the first dose.&#xD;
&#xD;
          4. A history of prescription or over-the-counter (OTC) drug use within 14 days prior to&#xD;
             the first dose.&#xD;
&#xD;
          5. A history of vitamin preparation or supplement use (including St. John's Wort and&#xD;
             ginseng) within 14 days prior to the first dose.&#xD;
&#xD;
          6. A history of strenuous physical activity within 72 hours prior to dosing.&#xD;
&#xD;
          7. A history of exposure to an investigational drug within 30 days or 7 half-lives of the&#xD;
             investigational drug, whichever was longer, prior to the first dose of investigational&#xD;
             drug in this trial.&#xD;
&#xD;
          8. A history of prior exposure to EGT0001474 or bexagliflozin at any time, or of exposure&#xD;
             to any other SGLT2 inhibitors within 3 months from screening or of participation in&#xD;
             previous bexagliflozin clinical trials.&#xD;
&#xD;
          9. A history of consumption of probenecid, rifampin, or verapamil within 3 months of&#xD;
             screening.&#xD;
&#xD;
         10. A screening ECG that demonstrated any one of the following: heart rate &gt;100 bpm, QRS&#xD;
             &gt;120 msec, QTc &gt;470 msec (corrected by Bazett's formula), PR &gt;220 msec (a subject with&#xD;
             PR &gt;220 msec was generally to be excluded, but exceptions may have been allowed at the&#xD;
             discretion of the Investigator), or any clinically significant arrhythmia.&#xD;
&#xD;
         11. A sitting blood pressure that was above 140/90 mmHg at screening. If the sitting blood&#xD;
             pressure at screening was above 140/90 mmHg, one repeat measurement could have been&#xD;
             taken. Subjects were to be excluded if the repeated sitting blood pressure was above&#xD;
             140/90 mmHg, but exceptions may have been allowed at the discretion of the&#xD;
             Investigator.&#xD;
&#xD;
         12. A positive result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV)&#xD;
             antibody, or for urinary drug or cotinine tests.&#xD;
&#xD;
         13. A history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         14. A history of febrile illness within 5 days prior to the first dose of investigational&#xD;
             drug.&#xD;
&#xD;
         15. A history of vaccination (with the exception of the flu vaccine) within 30 days prior&#xD;
             to the first dose of investigational drug.&#xD;
&#xD;
         16. An estimated glomerular filtration rate (eGFR) &lt; 80 mL/min/1.73 m2 or a history of&#xD;
             kidney transplant.&#xD;
&#xD;
         17. If male, who was not surgically sterile, unwilling to refrain from donating sperm,&#xD;
             and/or unwilling to use appropriate birth control when engaging in sexual intercourse&#xD;
             for a period of 30 days after discharge from the clinic.&#xD;
&#xD;
         18. Female subjects who were surgically sterile (i.e., have undergone partial or full&#xD;
             hysterectomy, or bilateral oophorectomy) or postmenopausal were eligible if they&#xD;
             tested negative on a urine pregnancy test.&#xD;
&#xD;
         19. Evidence of anemia if selected for probenecid study.&#xD;
&#xD;
         20. Evidence of abnormal liver function tests (total bilirubin &gt;1.5 x upper limit of&#xD;
             normal [ULN]); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
             &gt;2.5 x ULN.&#xD;
&#xD;
         21. If selected for the rifampin study, unwilling to refrain from the use of soft contact&#xD;
             lenses during the study.&#xD;
&#xD;
         22. Unwilling to forgo consumption of alcohol 72 hours pre admission and throughout the&#xD;
             study.&#xD;
&#xD;
         23. Unwilling to forgo consumption of grapefruit and grapefruit products from 7 days prior&#xD;
             to dosing through discharge from the clinic.&#xD;
&#xD;
         24. A history of recurrent yeast or urinary tract infections or any such infections in the&#xD;
             6 months prior to first dose.&#xD;
&#xD;
         25. A history of gout, glucose-6-phosphate dehydrogenase deficiency, or nephrolithiasis if&#xD;
             a candidate for the probenecid study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>March 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2021</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexagliflozin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Probenecid</mesh_term>
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03296800/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03296800/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid</title>
          <description>Subjects were dosed with bexagliflozin tablets, 20 mg, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.</description>
        </group>
        <group group_id="P2">
          <title>Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin</title>
          <description>Subjects were dosed with bexagliflozin tablets, 20 mg, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.</description>
        </group>
        <group group_id="P3">
          <title>Bexagliflozin, Then Verapamil and Bexagliflozin</title>
          <description>Subjects were dosed with bexagliflozin tablets, 20 mg, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
        </group>
        <group group_id="B2">
          <title>Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
        </group>
        <group group_id="B3">
          <title>Bexagliflozin, Then Verapamil and Bexagliflozin</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="9.69"/>
                    <measurement group_id="B2" value="35.3" spread="10.72"/>
                    <measurement group_id="B3" value="37.8" spread="11.24"/>
                    <measurement group_id="B4" value="37.2" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.3" spread="10.59"/>
                    <measurement group_id="B2" value="74.1" spread="11.31"/>
                    <measurement group_id="B3" value="78.9" spread="9.21"/>
                    <measurement group_id="B4" value="78.7" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.9" spread="8.28"/>
                    <measurement group_id="B2" value="169.2" spread="8.38"/>
                    <measurement group_id="B3" value="172.1" spread="10.17"/>
                    <measurement group_id="B4" value="170.7" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="2.73"/>
                    <measurement group_id="B2" value="25.9" spread="3.31"/>
                    <measurement group_id="B3" value="26.7" spread="2.46"/>
                    <measurement group_id="B4" value="27.0" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O2">
            <title>Study 1: Bexagliflozin and Probenecid</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
          </group>
          <group group_id="O3">
            <title>Study 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O4">
            <title>Study 2: Bexagliflozin and Rifampin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
          </group>
          <group group_id="O5">
            <title>Study 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O6">
            <title>Study 3: Bexagliflozin and Verapamil</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.675" spread="28.673"/>
                    <measurement group_id="O2" value="193.366" spread="22.098"/>
                    <measurement group_id="O3" value="97.811" spread="53.903"/>
                    <measurement group_id="O4" value="117.001" spread="60.097"/>
                    <measurement group_id="O5" value="159.355" spread="35.396"/>
                    <measurement group_id="O6" value="169.000" spread="24.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>118.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>111.12</ci_lower_limit>
            <ci_upper_limit>126.72</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>119.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.39</ci_lower_limit>
            <ci_upper_limit>151.59</ci_upper_limit>
            <other_analysis_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>106.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.81</ci_lower_limit>
            <ci_upper_limit>126.65</ci_upper_limit>
            <other_analysis_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin/Probenecid</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin/Rifampin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
          </group>
          <group group_id="O3">
            <title>Bexagliflozin/Verapamil</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bexagliflozin alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="2.000" upper_limit="4.000"/>
                    <measurement group_id="O2" value="2.000" lower_limit="2.000" upper_limit="4.083"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.000" upper_limit="8.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bexagliflozin + additional drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="2.000" upper_limit="4.017"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.017" upper_limit="4.000"/>
                    <measurement group_id="O3" value="3.000" lower_limit="2.000" upper_limit="4.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
        <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin/Probenecid</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin/Rifampin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
          </group>
          <group group_id="O3">
            <title>Bexagliflozin/Verapamil</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
          <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bexagliflozin alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.090" spread="35.950"/>
                    <measurement group_id="O2" value="12.190" spread="36.966"/>
                    <measurement group_id="O3" value="10.709" spread="44.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bexagliflozin + additional drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.894" spread="24.806"/>
                    <measurement group_id="O2" value="5.318" spread="49.740"/>
                    <measurement group_id="O3" value="11.675" spread="48.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
        <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <population>AUC0-t (from time 0 to time T) was used instead of AUC0-inf for Study 2 since AUC0-inf was not reported</population>
        <group_list>
          <group group_id="O1">
            <title>Study 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O2">
            <title>Study 1: Bexagliflozin/Probenecid</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
          </group>
          <group group_id="O3">
            <title>Study 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O4">
            <title>Study 2: Bexagliflozin/Rifampin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
          </group>
          <group group_id="O5">
            <title>Study 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O6">
            <title>Study 3: Bexagliflozin/Verapamil</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
          <description>Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <population>AUC0-t (from time 0 to time T) was used instead of AUC0-inf for Study 2 since AUC0-inf was not reported</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1118.741" spread="23.290"/>
                    <measurement group_id="O2" value="1583.188" spread="23.676"/>
                    <measurement group_id="O3" value="698.254" spread="43.945"/>
                    <measurement group_id="O4" value="601.334" spread="49.870"/>
                    <measurement group_id="O5" value="1025.101" spread="25.746"/>
                    <measurement group_id="O6" value="1003.931" spread="21.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>140.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>131.39</ci_lower_limit>
            <ci_upper_limit>151.26</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>86.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.24</ci_lower_limit>
            <ci_upper_limit>105.59</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>97.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.26</ci_lower_limit>
            <ci_upper_limit>106.26</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Glucose Excretion 0-48 hr</title>
        <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.</description>
        <time_frame>0 to 48 hours</time_frame>
        <population>Only subjects with data in the specific category is included</population>
        <group_list>
          <group group_id="O1">
            <title>Study 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin/Probenecid</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
          </group>
          <group group_id="O3">
            <title>Study 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O4">
            <title>Bexagliflozin/Rifampin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
          </group>
          <group group_id="O5">
            <title>Study 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin tablets, 20 mg; qd</description>
          </group>
          <group group_id="O6">
            <title>Bexagliflozin/Verapamil</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion 0-48 hr</title>
          <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.</description>
          <population>Only subjects with data in the specific category is included</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose (-12 - 0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.024"/>
                    <measurement group_id="O2" value="0.47" spread="1.160"/>
                    <measurement group_id="O3" value="0.02" spread="0.014"/>
                    <measurement group_id="O4" value="0.12" spread="0.180"/>
                    <measurement group_id="O5" value="0.02" spread="0.018"/>
                    <measurement group_id="O6" value="1.37" spread="1.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 12 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.04" spread="5.579"/>
                    <measurement group_id="O2" value="25.90" spread="5.214"/>
                    <measurement group_id="O3" value="31.50" spread="9.272"/>
                    <measurement group_id="O4" value="31.40" spread="7.363"/>
                    <measurement group_id="O5" value="31.14" spread="5.814"/>
                    <measurement group_id="O6" value="31.46" spread="14.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.28" spread="7.347"/>
                    <measurement group_id="O2" value="20.92" spread="4.358"/>
                    <measurement group_id="O3" value="19.43" spread="6.863"/>
                    <measurement group_id="O4" value="15.72" spread="7.259"/>
                    <measurement group_id="O5" value="22.30" spread="3.933"/>
                    <measurement group_id="O6" value="20.51" spread="5.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 - 36 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.04" spread="7.136"/>
                    <measurement group_id="O2" value="22.10" spread="6.826"/>
                    <measurement group_id="O3" value="21.51" spread="7.668"/>
                    <measurement group_id="O4" value="16.32" spread="6.370"/>
                    <measurement group_id="O5" value="24.54" spread="6.517"/>
                    <measurement group_id="O6" value="20.94" spread="6.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 - 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.15" spread="5.447"/>
                    <measurement group_id="O2" value="9.53" spread="3.114"/>
                    <measurement group_id="O3" value="6.99" spread="3.440"/>
                    <measurement group_id="O4" value="3.41" spread="2.318"/>
                    <measurement group_id="O5" value="11.31" spread="4.997"/>
                    <measurement group_id="O6" value="4.78" spread="2.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.73" spread="9.125"/>
                    <measurement group_id="O2" value="46.82" spread="8.530"/>
                    <measurement group_id="O3" value="50.93" spread="15.606"/>
                    <measurement group_id="O4" value="47.12" spread="13.790"/>
                    <measurement group_id="O5" value="53.44" spread="8.712"/>
                    <measurement group_id="O6" value="51.97" spread="13.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.67" spread="16.083"/>
                    <measurement group_id="O2" value="78.44" spread="15.653"/>
                    <measurement group_id="O3" value="79.43" spread="24.490"/>
                    <measurement group_id="O4" value="66.86" spread="19.564"/>
                    <measurement group_id="O5" value="89.29" spread="16.461"/>
                    <measurement group_id="O6" value="77.69" spread="16.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data were collected from Day 0 up to Day 7 for study 1, Day 0 up to Day 8 for study 2 and Day 0 up to Day 6 for study 3 after drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study 1: Bexagliflozin Alone</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd</description>
        </group>
        <group group_id="E2">
          <title>Study 1: Bexagliflozin and Probenecid</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Probenecid: Probenecid tablets, 500 mg; bid</description>
        </group>
        <group group_id="E3">
          <title>Study 2: Bexagliflozin Alone</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd</description>
        </group>
        <group group_id="E4">
          <title>Study 2: Bexagliflozin and Rrifampin</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Rifampin: Rifampin 600 mg (2 x 300 mg capsules); qd</description>
        </group>
        <group group_id="E5">
          <title>Study 3: Bexagliflozin Alone</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd</description>
        </group>
        <group group_id="E6">
          <title>Study 3: Bexagliflozin and Verapamil</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg; qd&#xD;
Verapamil: Verapamil hydrochloride tablets, 120 mg; qd</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator has no right to publish the trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos Sub, LLC</organization>
      <phone>(508) 688-4221</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

